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Big Data Approaches to Improving the Identification of Drug or Disease
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Muying Wang, PhD
University of Pittsburgh, 2020
Advances in science and technology have substantially changed drug research and devel-
opment (R&D) processes. However, the efficiency of drug R&D, described in the number
of new drugs approved per billion US dollars spent, dramatically declined between 1950 to
2010. Some of the main causes to the attrition include the cautious regulator, the potential
risk in chemical screening methods for early drug discovery, and the lack of understanding
of disease mechanisms. In order to improve the efficiency and productivity in drug R&D,
more powerful tools are needed to assist in prediction forecasting and decision making in
drug development.
This dissertation describes my work in developing computational approaches to provide
better understanding of drug or disease mechanisms at the systems level. The first project
involves collaboration with RIKEN institute in Japan for innovation of influenza vaccine
adjuvant. We performed comparative analysis of RNA-Seq data from mice treated with dif-
ferent adjuvants to identify mechanisms supporting adjuvant activity. In the second project,
we predicted immune cell dynamics by linear regression-based algorithms or statistical tools,
and suggested a new approach that can improve the discovery of key disease-associated genes.
In the third project, we found that the network topological features, especially network be-
tweenness, predominantly define the accuracy of a major drug target inference algorithm.
We proposed a novel algorithm, TREAP, which integrated betweenness and differential gene
expression and can accurately predict drug targets in a time-efficient manner. Through the
projects above, we have demonstrated how computational algorithms can assist in mining big
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Preface
This work and my graduate program started with the interests in traditional Chinese
medicine and pharmacy. As a teenager, I read several books and articles about a Chinese
physician, Zhongjing Zhang. Living around 1800 years ago, he not only summarized and
established the principles of Chinese medicine but was also revered for treating the disad-
vantaged, regardless of their social status. I have been inspired by the advanced ideas in
his works, such as regarding the human body as a system, designing personal treatments,
controlling toxicity of a prescription, and utilizing one prescription for treating multiple
diseases. For example, eyes are believed to be a dependent to the liver. Therefore, any
symptoms of eyes are reflection of disorders in the liver, and to treat the eyes, one should
diagnose and react to the actual problem with the liver. What’s more, with sympathy for
patients, Zhang’s drug prescriptions were designed as inexpensive as possible while maxi-
mizing their effects. With him as an example, I intend to work on life science or healthcare
research and innovation that can increase efficiency of drug treatments, improve patients’
experience, and lower the cost for society.
Living in 21st century, we can achieve better and more efficient diagnosis and treatment.
However, people are still facing challenges in some complex diseases, such as cancer, whose
mechanisms or treatments have not yet been uncovered. Some of the barriers lie in the
lack of principles similar to Chinese medicine which can explain human body and disease
pathology at the systems level.
When I was in high school, I learned about technologies related to big data and bioin-
formatics approaches. I found it promising to use these approaches to understand disease
mechanisms and innovate new drugs, because they have potential in capturing characteris-
tics of biological samples at various levels, from a single cell to a live animal. Understanding
the changes that computational tools and artificial intelligence will make to the life science
and healthcare industry, I decided to learn programming during my graduate program and
it is my motivation for this work.
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1.0 Background
1.1 Challenges of Drug Research and Development
Advances in science and technologies since 1950s have substantially changed drug re-
search and development (R&D) processes. For example, high-throughput screening can con-
duct thousands of tests simultaneously, and it has been broadly utilized in pharmaceutical
industry and contributed to the discovery of drugs, such as chemokine receptor antagonists
[5]. Other breakthroughs associated with pharmaceutical industry include but are not lim-
ited to DNA sequencing and X-ray crystallography. However, the efficiency of drug R&D,
described in the number of new drugs approved per billion US dollars spent (inflation ad-
justed), dramatically declined between 1950 to 2010 [6].
The main causes to the attrition in efficiency and existing challenges in drug R&D lie
in (1) the cautious regulator, (2) the potential risk in chemical screening methods for early
drug discovery, and (3) the lack of understanding of disease mechanisms [6], which will be
further explained in the following sections.
1.1.1 The Cautious Regulator and Clinical Trial Failures
The cautious regulator has shown obvious impact on the efficiency of drug R&D. After
the tragedy of thalidomide, the U.S. Food and Drug Administration (FDA) tightened the
regulation on new drugs, so that the efficiency of drug R&D decreased from 1960s to 1970s
[6]. On the contrary, in 1990s, the efficiency temporarily increased as the FDA cleared
backlog and lowered the regulatory barriers for HIV drugs [6].
The regulatory processes for the introduction of new drugs have been profoundly changed
since 1950s. Currently, a typical drug development pipeline contains 5 stages as described
by the FDA: (1) discovery and development, (2) preclinical research, (3) clinical research,
(4) FDA drug review and (5) FDA post-market drug safety monitoring [7] (Figure 1).
1
Figure 1: Overview of the drug development pipeline and clinical trial phases.
At the stage of discovery and development, new drug candidates are often discovered
through improved understanding of disease pathology or tests of molecular compounds, such
as high-throughput screening. Experiments are performed to understand the efficacy, mech-
anisms of action, dosage and toxicity of promising drug candidates [8]. The information
gathered help to decide which candidates will proceed to preclinical and clinical researches.
For preclinical research, the dosing and safety of drug candidates are tested in vitro or in
vivo before they are tested in people [9]. The findings assist in decision-making for clinical
trials.
The clinical research, which contains four phases, is designed to study the efficacy, tox-
icity and dosage of drug candidates by testing them in people [10] (Figure 1). In Phase
I, drug candidates are tested in around 20 to 100 healthy volunteers or people with the
disease/condition to understand their safety and dosage. According to FDA, about 70%
of all candidates will move to Phase II [10]. In Phase II, several hundred people with the
disease/condition are tested for a few months to two years to collect data about the efficacy
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and side effects of drug candidates. At this phase in clinical trials, merely 33% of candidates
can move to Phase III [10]. Phase III is the last step before FDA review and approval. The
studies are larger in scale, with 300 to 3000 people with the disease/condition, and longer in
duration, one to four years for the length of studies. This phase provides most of the data
on the safety and the benefits that a drug candidate can offer to a specific population. Only
25-30% of drug candidates can move forward to FDA review. Usually after sufficient data is
collected from Phase I to Phase III trials, a New Drug Application is filed and the FDA will
make a decision on whether to approve this drug. Once it is approved, the drug developer
will be able to market the drug, and Phase IV trials are carried out to monitor its safety
[11].
Based on the success rates of each phase, the overall rate for a drug candidate to pass
through Phase I to III and be approved is around 7%. It is necessary to carefully study the
reasons for failures in clinical research and optimize the drug development pipeline to improve
the efficiency accordingly [6, 12]. From 2008 to 2015, the primary cause to failure in Phase
II and Phase III maintained to be insufficient efficacy, which accounted for around 50-65%
of all failures in each phase [12, 13, 14]. This is surprising because early drug discovery and
preclinical tests are supposed to diminish the possibility of failures due to efficacy. What’s
more, the percentage of insufficient efficacy at Phase III was comparable with Phase II. The
secondary cause was safety issues, and the percentage was around 15-35% in each phase.
Combining the primary and secondary causes, the clinical trial failures caused by insufficient
efficacy or safety issues accounted for 70-85% of all failures at Phase II or III. The rest of
the causes are commercial, strategic and operational concerns or issues. The above suggests
that currently procedures in terms of early drug discovery and preclinical tests may need
improvements to reduce failures in clinical research.
1.1.2 The Potential Risk in Chemical Screening Methods for Early Drug Dis-
covery
New drugs approved by the FDA in the past few years can be roughly divided into two
groups, small molecule drugs and biologics, and the small molecule drugs have dominated
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the new drug approvals in each year from 2015 to 2018 [15, 16, 17, 18]. For example, 42
small molecule drugs and 17 biologics were approved in 2018, where the small molecule drugs
accounted for 71% [15]. This section will focus on the challenges in developing new small
molecule drugs.
The screening of promising chemical compounds, either through experimental or com-
putational platforms, have been well developed and established in pharmaceutical industry
for early drug discovery. The target-based discovery of small molecule drugs usually involves
the following steps: target identification, compound screening, optimization and candidate
selection [5, 6, 19]. Through improved understanding of a certain disease, key factors that
affect disease pathology or progression are discovered and some of them have potential in
interacting with small molecules to treat the associated disease. These key factors can be
proteins, DNAs or RNA molecules and are referred to as targets [19]. At the step of com-
pound screening, such as high-throughput screening, a chemical library is screened against
the target to identify active chemical compounds, called hits. Lead compounds are identified
by optimization and validation of the hits from screening methods to improve activity and
selectivity [19]. The resulted leads are further improved on deficiencies such as off-target
effects, and hopefully will lead to a drug candidate for preclinical and clinical research.
For screening of chemical compounds, there have been a variety of technologies to identify
hits, e.g. high-throughput screening, structure-based design, fragment screening or virtual
screening. Maraviroc,a chemokine receptor antagonist invented by Pfizer, is an instance
of successful drug innovation through application of high-throughput screening [5]. The
Pfizer chemical library, containing around 500,000 compounds, was screened against the
CC-chemokine receptor 5 (CCR5). A weak agonist hit was identified by the screening tests
and led to a series of structure-activity relationship studies. There were 4,000 and more
compounds synthesized and optimized to achieve the desired antiviral activity [5, 20].
The major advantage of chemical screening methods is that they are faster than tradi-
tional methods by several orders in speed while maintaining reasonable costs [6]. It only
takes several months to screen a set of one million chemical compounds with controllable
quality [5]. However, the overall drug R&D has not displayed a turnover in efficiency since
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the introduction of screening methods. The success rate of a drug candidate to pass all
clinical trials remains stable, and the efficiency of drug R&D characterized by money spent
on each approved drug also keeps declining.
The underlying assumption of screening methods is that good performance in screening
tests, such as high binding affinity to certain targets, can lead to promising drug candidates
that are effective in humans to treat the associated disease. However, it is risky to fully rely on
this assumption for two reasons. One reason is that it requires much accurate understanding
of the disease and identification of the potential targets [21, 5, 22, 23]. A good target with
potential to be drugged against ought to be a key factor of disease pathology and not cause
dramatic side effects. If a wrong target was identified, the hits obtained from screening tests
will end up in failure eventually. The other reason is that screening tests naturally lack
the context of the complex biological system. Assuming the targets are the right ones to
be tested against, the performance of chemical compounds in screening studies, either good
or bad, cannot be used as solid proof to determine whether a compound would be active
and safe in human or it should be eliminated from further studies [6]. Ideally, all types of
tests, including both screening and animial tests, should be conducted and the results be
integrated to maximize the success rate of a hit leading to a drug candidate and the FDA
approval. However, this is not economically feasible. There need more powerful approaches
that can predict and integrate the information at systems level to aid drug discovery and
development.
1.1.3 Lack of Understanding of Disease Mechanisms
As described in the section named “The potential risk in chemical screening methods for
early drug discovery”, screening methods are based on target identification, which requires
deep understanding of disease mechanisms [21, 5, 22, 23]. And it has been explained that the
quality of identified targets is crucial for success rate of screening methods. In addition, the
section of “The cautious regulator and clinical trial failures” has explained that the primary
cause of failures in Phase II or III is insufficient efficacy instead of drug safety. In the recent
work by Cook et al, the research team analyzed the drug projects closed between 2005 to
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2010 at AstraZeneca. They found that 40% of closed projects due to insufficient efficacy
were claimed to lack data on a clear linkage of the target to the disease mechanism [21]. By
contrast, projects with higher confidence in target validation or better understanding of the
connection between the target and disease were less likely to fail due to efficacy issues [21].
However, understanding disease mechanisms and pathology remains challenging for some
diseases, such as cancer and respiratory diseases [24, 25, 26, 27]. For example, drug develop-
ment for influenza resulted illnesses are limited because of the lack of characterization of the
immune response during influenza infection. For cancer, there have been major limitations
of the animal models used in associated studies [25].
1.2 Challenges in Using High-throughput Biological Data to Reveal Disease
Mechanisms
High-throughput biological data, including abundance data (e.g. mRNA level) and in-
teraction data (e.g. PPI), has been growing exponentially in availability during the past two
decades, fueling a rapid progression in systems biology research. Transcriptomes of single
cells, tissues under different conditions, and disease states at multiple scales have been gen-
erated as a result of continually improved technologies [28]. In the past decade, thousands
of papers about the two dominant measurements of transcriptional profiles (microarray and
RNA-Seq) have been published per year [28].
Transcriptional profiling is a promising approach to characterize the regulatory behavior
and dynamics of the immune response as well as the associated influence on physiopathology.
In addition, time-series experiments of transcriptome analysis are able to characterize global
dynamical change in a system and biological functions of genes which may indicate the rele-
vant regulation pathways [29]. Different bioinformatics tools have been developed to analyze
the transcriptomic data, [30, 31, 32, 33] many of which could also lead to clinical improve-
ments. Potential applications of computational algorithms include faster, more accurate
diagnosis of diseases, suggestion of personal and high-targeting treatment, and monitoring
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of trends in immunopathology. Although these tools are designed for varying diseases, there
may be overlap in strategy applicability.
By far most research has focused on identifying differentially expressed genes using tran-
scriptomic data through statistical tests or inferring pathway activity by a variety of meth-
ods. However, there remain challenges in interpretation of complex tissue level or multiscale
transcriptomic data. One significant confusion is the understanding of gene regulation. Ex-
pression signals of genes from disease-perturbed samples might increase or decrease during
a period of time. But this might not be an indication that the genes have been activated or
suppressed due to the perturbation, since changes of cellular composition in the biological
sample might also induce the fluctuations of gene expressions. Possible composition change
in cell population induced by diseases includes migration, proliferation, and differentiation.
Transcript changes in cellular demographics and changes in gene regulation in temporal (e.g.
time-point) samples should be treated separately. In addition, transcriptomic data has lim-
ited power when identifying disease associated genes or pathways. It has been shown that
disease-related genes sometimes yield low gene expression levels [34] in the tissue or are less
variated across time [35]. Therefore, more powerful and systems approaches are needed to
better interpret the disease mechanisms.
1.3 Dissertation Overview
Advances in life science technologies have enabled researchers to explore exponentially
growing biological datasets. These datasets include data ranging from the molecular level
to cellular or tissue level. However, it remains a challenge to remove the noise and interpret
the data to gain insights in disease pathology and drug mechanisms. In this work, we
demonstrate how computational or statistical methods can assist in identifying disease or
drug mechanisms.
Chapter 2 focuses on the statistical analyses of gene expression data of samples treated
with four different types of influenza vaccine adjuvants through collaboration with RIKEN
(Japan). Differentially expressed genes were identified by comparing the test samples with
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the control, and the enriched functional annotations were analyzed to help understand the
mechanisms of each adjuvant. The identified mechanisms provided meaningful insights and
research direction in developing the novel adjuvant.
Chapter 3 takes various types of deconvolution algorithms to predict dynamic changes in
immune cell quantities induced by influenza virus infection. There are two motivations for
the prediction analysis. One is that changes in immune cell quantities, especially infiltration
of certain immune cells to the lung, have been found to be relevant to deadly outcomes in
disease pathology. The other motivation is that gene expression needs to be adjusted for
changes in cell quantities to reveal differential expression caused by the perturbation of a
disease. Identification of key disease-associated genes were much improved by using adjusted
gene expression.
Chapter 4 shows that network topology predominantly determines the prediction accu-
racy of a drug target inference algorithm, ProTINA, published in former literature. Based
on the findings, a novel target inference algorithm was proposed and showed better perfor-
mance than ProTINA. This algorithm integrates protein betweenness and differential ex-
pression representing network topology and drug signatures, respectively, and is faster and
more tractable than ProTINA. This chapter also discusses how the algorithm can be applied
to different research scenarios. Chapter 5 focuses on the conclusions, accomplishments and
potential future work of the previous chapters.
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2.0 Comparing Gene Expression from Mice Treated with Different Influenza
Vaccine Adjuvants
2.1 Introduction
Seasonal influenza infection is a threat for human beings. Induced by Influenza A (H1N1)
viruses, the most recent global pandemic happened in 2009. Yearly influenza viruses could
be lethal for people at high risk: people of 65 years old or older, people with chronic diseases,
pregnant women or young children [36, 37]. According to Centers for Disease Control and
Prevention, influenza A(H3N2) viruses and influenza B viruses circulated in the United
States during the 2017-2018 influenza season, which caused an estimated 45 million influenza
illnesses and 61,000 deaths [38]. Though the numbers vary, influenza viruses result in millions
of sicknesses, hundreds of thousands of hospitalizations, and thousands or tens of thousands
of deaths every year in the United States.
Infection with influenza raises challenges in clinical diagnosis and treatment. There are
several antiviral drugs available which benefit people at high risk. But they usually work
only if treatment starts within the first 2 days of illness. Most of these drugs are not available
for young children, such as baloxavir marboxil (Xofluza). Vaccines remain the best strategy
against the influenza virus infection.
Transcriptome analysis can help to characterize immune response or gene regulations
induced by influenza vaccination and reveal immune mechanisms promoting vaccine efficacy
and guide the design of new adjuvants. In this project, we obtained RNA-Seq gene expres-
sion data from mice treated with four different vaccine adjuvants from the collaborators at
RIKEN (Japan). These adjuvants are AddaVax, aluminum precipitates (Alum), Complete
Freund’s Adjuvant (CFA) and CTA1-DD, where Alum and CFA serve as controls. Alum
was invented 90 years ago and has been widely used as vaccine adjuvant for a variety of vac-
cines. Squalene-based AddaVax and cholera toxin-derived CTA1-DD have been developed
in recent years. CFA is derived from inactivated and dried mycobacteria and currently is for
research usage only. With our collaborators, we found that AddaVax is the most significant
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and promising for future vaccine adjuvant development. Our functional annotation analysis
found that much of the activity was associated with vitamin D3 activity and provided future
research direction in developing influenza vaccine adjuvant. This is also a demonstration of
transcriptomic data and computational approaches in aiding vaccine development. Please
note that this is a side project for training purposes, and in this chapter we focus on the
statistical analysis of RNA-Seq gene expression data.
2.2 Methodology
2.2.1 Normalization and Statistical Analysis of RNA-Seq Data
The spleen and lymph node organs were extracted from the mice treated with vaccines
containing one of four different types of adjuvants, namely AddaVax, Alum, CFA and CTA1-
DD (where Alum and CFA serve as controls), and their mRNA levels were measured by
RNA-Seq analysis. There were 3 biological replicates for each adjuvant or organ type.
The RNA-Seq reads were obtained from Dr. Hidehiro Fukuyama at RIKEN (Yokohama,
Japan), and the normalization or statistical analysis were performed by the CLC Genomics
Workbench (version 10.0.1). The reads were mapped to the annotated mouse genome, “Mus
musculus ensembl v80 Sequence”, and transcripts per million (TPM) were calculated as ex-
plained by Li et al. [39]. TPM counts were normalized by the trimmed mean of M values
(TMM) method [40] to calculate effective library sizes. The count per million (CPM) values
were calculated for each gene by using the effective library sizes obtained from TMM method,
and log2-scaled CPM values were utilized for principle component analysis (PCA). For dif-
ferential expression analysis, each gene was modeled by a Generalized Linear Model (GLM)
assuming negative binomial distribution, and fold changes were calculated accordingly. The
p-values were obtained by performing Wald test.
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2.2.2 Functional Annotation Enrichment Analysis
Differentially expressed genes (fold change > 1.5, and p-value < 0.05) were obtained as
explained in the section above. Their significant functional annotations were obtained from
DAVID [41, 42] (enrichment score > 2).
2.3 Results
2.3.1 Identifying Differentially Expressed Genes in RNA-Seq Data from
Influenza-infected Samples Pre-treated with Various Adjuvants
Through differential expression analysis, we found lymph node samples are more signifi-
cant than spleen samples, and AddaVax is the most significant and promising adjuvant for
future development (Figure 2). Using Alum as control, 475 and 630 genes are differentially
expressed in samples treated with CTA1-DD and AddaVax, respectively (fold change > 1.5,
and p-value < 0.05). If CFA is used as control, there are 13 and 430 differentially expressed
genes for CTA1-DD and AddaVax, respectively, under the same thresholds for fold change
values and p-values. Therefore, AddaVax is the most significantly different from control
adjuvants (Figure 3).
As the comparisons by using Alum as control have shown more significant results (Figure
2), we focused on differentially expressed genes from CTA1-DD or AddaVax versus Alum
for functional annotations. The enrichment scores of significant genes’ functional annotation
clusters were obtained from DAVID [41, 42]. These genes are mostly enriched in immune
response (biological process), binding (molecular function) and extracellular region (cellular
component) as shown in Table 1. Especially, significant genes of AddaVax are enriched in
collagen, lectin and steroid biosynthesis 1. This has provided inspiration for our collabo-
rators to exploit associated biological processes and find that the mechanism of AddaVax
is associated with vitamin D3 activity. A vitamin D3 analog adjuvant, oxarol, has been
reported in the recent publication [3], and our collaborators are preparing for another article
on associated research.
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Figure 2: The number of differentially expressed genes in spleens (a)(b) or lymph nodes
(c)(d). In (a)(c), Alum serves as the control, and CFA is the control in (b)(d).
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Figure 3: (a) CPMs of 3 adjuvant samples (AddaVax, Alum and CTA1-DD) are log2-scaled
and averaged respectively. The first two principle components are shown here, color coded
by adjuvant type. (b) Comparison between average log2-scaled CPMs of AddaVax and
Alum. Up-regulated significant genes (FDR < 0.25) and down-regulated significant genes
are colored green and red.
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Table 1: Significant genes (FDR < 0.25) in comparison between AddaVax and Alum samples
are analyzed by DAVID for annotations. Annotation terms are summarized with referring
enrichment scores listed in the table.
Annotation Cluster Enrichment Score
Immune response to virus 33.9
Signal peptide 25.9




Double-stranded RNA binding 5.1
Endoplasmic reticulum 4.7
Immunoglobulin domain 4.6
Zinc finger region 4.1
Double-stranded DNA binding 4.1
Steroid biosynthesis 3.4
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3.0 Predicting Host Immune Cell Dynamics and Key Disease-Associated
Genes Using Tissue Transcriptional Profiles
3.1 Introduction
Accurately identifying and quantifying the immune cells is critical to understanding both
how the body manages disease and how immune mismanagement may increase the overall
disease pathology (e.g., immunopathology). The behavior of immune cells is a primary factor
in the overall disease pathology [43, 44, 45, 46, 47, 48, 49]. The immune response is a complex
process that coordinates the activation, migration and differentiation of a large variety of
immune cells [50, 51, 52, 53]. A very common factor of disease pathology is overly aggressive
or dysregulated immune responses in which diseased tissues are observed to have abnormally
high numbers of inflammatory immune cells. A specific example is lethal influenza infections,
which are often characterized by extremely high quantities of macrophages or neutrophils
that infiltrate into lungs [54, 55, 56, 57]. It has also been shown in influenza infection studies
that modulating inflammatory immune cell counts by interfering with immune cell trafficking
or activation can significantly improve infection outcomes [58, 59, 60]. An accurate quantifi-
cation of immune cells is essential to identifying the mechanisms of disease pathology and
can provide insights in innovating treatments.
While cell count data is necessary to mathematically model disease development, such
data is often limited and not nearly as accessible to the research community as genomics
data. Fluorescence-activated cell sorting (FACS) is one of the most common methods to
quantify cells in a sample. However, FACS requires significant amount of tissue for analysis,
which complicates the design of experiment [61]. Moreover, FACS data repositories are not
yet well established, although ongoing efforts such as ImmPort [62] are aiming to improve
this. Gene expression data on the other hand is widely available in curated repositories, such
as GEO [63]. To support identifying the mechanisms behind disease pathology and promote
mathematically modeling the complex systems linking disease and immune responses, it
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would be a major benefit to be able to exploit gene expression data to identify and count
the immune cells in a sample.
The computational challenge is to use the changes in the number of RNA transcripts
within a tissue that is caused by the changing numbers of immune cells to infer, i.e., count,
the number of immune cells themselves. Both the signaling pathways activated by a disease
and the increased localization of immune cells result in changes in the number of RNA tran-
scripts within a tissue (see Figure 4) [64, 29]. Most genomics research focuses on identifying
differentially expressed genes by comparing gene expression from diseased tissue samples
with the control. However, given how immune cell infiltration impacts RNA transcript
counts, one should be able to infer the changes in numbers of immune cells by examining
the expression data. It is also significant to consider that without adjusting for changes in
cellular composition, the obtained differentially expressed genes may include false positives
that are not related to regulation activities but due to changes in cell populations. Compu-
tational approaches based on gene expression data, i.e., deconvolution algorithms, have been
developed to address these issues and can assist in the identification of gene regulations.
Deconvolution algorithms attempt to quantify cell counts in a mixed sample by using
gene expression data [65, 66]. The expression profiles that can be analyzed by deconvolution
algorithms include tissue samples collected from animals (e.g., mouse lung tissue samples
infected by influenza viruses [29]) and clinical samples from patients (e.g., blood samples
from systemic Lupus erythematosus patients [67]). Figure 4b provides a summary of the
algorithms used in this study. Two general strategies have been proposed. One takes a
bioinformatics approach and uses longitudinal clustering of time-series data to isolate sets
of genes and then associates the gene sets with candidate cell types using statistical tests,
such as cell type enrichment (CTen) [64, 29]. In this approach, the gene expression patterns
are assumed to be correlated with dynamic changes of enriched cell types. This strategy
has advantages: firstly, no prior knowledge of the cellular composition in the test sample is
required; secondly, all time points are considered simultaneously, and the method can easily
be extended over many experimental conditions.
The other common strategy postulates that tissue can be modeled as a linear combination
of gene expression profiles derived from pure cell populations. In general, these approaches
16
assume
A · x = b, (3.1)
where A is a n×p matrix of expression intensities of p kinds of pure cells for n genes [65, 68],
b is a vector of gene intensities in the test sample, and x is a vector of proportions for cell
types in the matrix A. Since n is usually larger than p, the linear problem is overdetermined
and different regression strategies are applied in various algorithms. Cell fractions are solved
through simulated annealing [65, 68], bounded linear least-squares regression (LLSR) [67],
quadratic programming in digital sorting algorithm (DSA) [66], elastic net regularization in
digital cell quantification (DCQ) [69], and a modified support vector regression (v-SVR) in
a tool named the cell-type identification by estimating relative subsets of RNA transcripts
(CIBERSORT) [70]. These algorithms require information of cell composition in the sample
and reference gene expressions of pure cells. Both requirements can limit their application
in inference.
An unexamined question is how accurate these deconvolution algorithms are for predict-
ing cell quantity changes in animal-derived tissue sampled over time (i.e., dynamic data) and
how to utilize their predictions to improve the identification of gene regulation related to the
disease. Most deconvolution algorithms are only tested by simulated expression data [71],
or data from artificial samples comprised of three or four distinct cell/tissue types [66, 67].
Seldom is algorithm performance examined by in vivo collected tissue samples, such as whole
blood samples [67]. To better understand performance, we evaluate four representative de-
convolution algorithms: CTen [64], modified LLSR (referred to as MLLSR in the following)
by Abbas et al. [67], CIBERSORT [70] and DCQ [69] (Figure 4b), by a common microarray
dataset of influenza-infected lung tissue sampled at multiple time points [29]. Estimates
from each deconvolution algorithm are compared with cell count data measured by FACS
under the same experimental conditions. We then propose a new approach to identifying
significant genes associated with disease by application of predictions from deconvolution.
We find that the ranking is significantly increased for important genes known to be factors of
virus replication and disease pathogenesis, after adjusting the bias of differential expression
analysis due to immune cell infiltration. Lastly, we conclude with a discussion on how cell
17




All mouse experiments were performed following the University of Tokyo’s Regulations
for Animal Care and Use, which are approved by the Animal Experiment Committee of the
Institute of Medical Science, University of Tokyo (approval number: PA10-13). All exper-
iments involving H5N1 virus were performed in biosafety level 3 containment laboratories
at the University of Tokyo, with the approval by the Ministry of Agriculture, Forestry, and
Fisheries, Japan.
3.2.2 Microarray Analysis of Mouse Lung Tissue
Complete and detailed methods for infection, tissue collection and tissue treatment
to perform lung gene expression analysis for the mice used in this study are reported
in Shoemaker et al. [29]. Briefly, 42 mice per cohort were inoculated with 105 plaque-
forming unit per gram of lung (PFU) of the A/Kawasaki/UTK-4/09 H1N1 virus (H1N1),
A/California/04/09 H1N1 virus (pH1N1), or the A/Vietnam/1203/04 H5N1 virus (H5N1).
A cohort of animals mock-infected with PBS (phosphate-buffered saline) served as the con-
trol for a total of 168 mice. At 14 time points, three mice per cohort were humanely
sacrificed, their lungs harvested, and the left-lower section used for gene expression analysis
by single-color microarray (the remaining sections were used for cytokine assay and West-
ern blot analysis). Data was background corrected and then quantile normalized using the
“limma” R package [72] and are available in the gene expression omnibus (GEO) repository
(GSE63786).
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Figure 4: Overview of deconvolution algorithms. (a) Gene transcript counts change as the
cellular makeup of a sample changes. Deconvolution algorithms postulate that the change
in the cellular makeup of the tissue can be inferred from the tissue’s gene expression by
exploiting the transcriptional profiles of pure cells. (b) Inputs, mathematical operations and
outputs of the four deconvolution algorithms reviewed in this paper.
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3.2.3 Flow Cytometry
Five mice per time point per cohort were infected with 105 PFU of virus. Five un-
infected (näıve) mice served as the negative control. Lungs were collected from mice and
incubated with Collagenase D (Roche Diagnostics; final concentration: 2 g/mL) and DNase
I (Worthington; final concentration: 40 U/mL) for 30 min at 37 ◦C. Single-cell suspensions
were obtained from lungs by grinding tissues through a nylon filter (BD Biosciences, San
Jose, CA, US). Red blood cells (RBCs) in a sample were analyzed using an RBC lysing
buffer (Sigma-Aldrich, St. Louis, MO, US). Samples were resuspended with PBS containing
2 mM EDTA and 0.5% bovine serum albumin (BSA), and the cell number was determined
using a disposable cell counter (OneCell, Fine Plus International, Kyoto, Japan). To block
nonspecific binding of antibodies mediated by Fc receptor, cells were incubated with puri-
fied anti-mouse CD16/32 (Fc Block, BD Biosciences). Cells were stained with appropriate
combinations of fluorescent antibodies to analyze the population of each immune cell subset
(see Table 2). The following antibodies were used: anti-CD49b (DX5: BD Biosciences),
anti-FcεRI (MAR-1: eBioscience), anti-c-kit (2B8: BD Biosciences), anti-CD45 (30-F11:
eBioscience), anti-CD11b (M1/70: BD), anti-CCR3 (83101: R&D), anti-F4/80 (BM8; eBio-
science), anti-CD11c (HL3: BD), anti-Gr-1 (RB6-8C5: BioLegend), anti-NK1.1 (PK136: BD
Biosciences), anti-B220 (RA3-6B2: BD Biosciences), anti-CD3ε (145-2C11: BD Biosciences),
anti-CD4 (RM4-5: BioLegend), anti-CD8α (53-6.7: BioLegend), and CD69 (H1.2F3: BD
Biosciences). All samples were also incubated with 7-aminoactinomycin D (via-probe, BD
Biosciences) for dead cell exclusion. The data of labeled cells were acquired on a FACSAria
II (BD Biosciences) and analyzed with FlowJo software version 9.3.1 (Tree Star). To eval-
uate the statistical significance of cell counts across time, we computed false discovery rate
(FDR) values by comparing cell counts at each time point and uninfected (naive) mice.
3.2.4 Prediction of Cell Fractions by MLLSR, CIBERSORT and DCQ
Microarray data of 17 cell types were gathered to construct a library of gene expression
profiles from populations of a single cell type for deconvolution by MLLSR and CIBERSORT.
These cell types included: B cell, Kdo (12h) stimulated B cell [73], näıve CD4+ T cell,
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natural CD4+ regulatory T cell [74], resting näıve CD8+ T cell, resting memory CD8+ T
cell, stimulated näıve CD8+ T cell, stimulated memory CD8+ T cell [75], immature dendritic
cell (imDC), mature DC (maDC), a unique subset of regulatory DC (sDC), IL-10 treated
sDC [76], lung [29], macrophage [77, 78], LPS (6h) stimulated macrophage [78], monocyte
[79], and NK cell [80]. Data was background corrected (monocyte data not corrected due to
unavailability) and then quantile normalized. Lowly-expressed genes were excluded (intensity
> 256 or log-scaled intensity > 8) based on the assumption that large intensity values benefit
identification of various cell types and deconvolution of gene expression reference. Gene
markers of a certain cell type in the library were selected by sorting the ratio of the intensity
of a gene for the cell type divided by the average of the same gene for all other cell types.
Top 100 genes with the highest ratios of each cell type and their expression intensities were
collected as information of pure cells that serve as matrix A in regression. The intensities
of these gene markers in an infected lung tissue sample served as the input as b to MLLSR
and CIBERSORT. MLLSR was rebuilt in R according to the literature. Equation (1) is
solved by the R function ‘lsfit’ and the minimum negative coefficient is removed until there
is no negative value [67]. Analysis by CIBERSORT was implemented online with settings
as default. It uses ν-SVR, which minimizes both a loss function and a penalty function.
CIBERSORT contains a feature selection step, in which less-variated genes are discarded to
reduce overfitting. In the last step, negative coefficients were set as zeros and all coefficients
are scaled to sum of one [70].
DCQ does not require or accept user-defined information of pure cells, and it depends
on an immune cell compendium that consists of a collection of 61 cell surface markers for
223 diverse cell types (213 of them are immune cells) and expression profiles of these cell
subsets obtained from ImmGen Project [81]. Intensities of all genes available in lung tissue
microarray data were uploaded to DCQ. As suggested [69], preprocessing of the data was
performed by log-scaling and subtracting the control sample, and every entry was divided
by the global standard deviation. The parameters, number of repeats and lambda.min, were
left as default.
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3.2.5 Gene Co-Expression Analysis by WGCNA and Cell Enrichment Analysis
by Cten
Microarray datasets of mouse lung tissues at 14 timepoints (0, 3, 6, 9, 12, 18, 24, 30,
36, 48, 60, 72, 120, and 168h) after infection by H1N1, pH1N1, and H5N1 were obtained
from literature [29] (methods summarized above). For each strain, a gene was differentially
expressed if it was significant for at least one time-matched comparison with mock samples
(fold change > 2; FDR < 0.01). Log fold change values of these differentially expressed genes
were utilized for the construction of the co-expression network by the WGCNA package [82]
in R. Block-wise network construction was implemented for pH1N1 and H5N1 due to the
large size of their datasets. A soft-thresholding power of 8, 9, and 8 was set respectively for
H1N1, pH1N1, and H5N1, based on scale-free topology fitting (Figure 17). Modules were
not merged (height cut = 0) for all strains, because merging modules can generate lower
correlations among genes within a module [29]. Module eigengenes and module membership
of genes were calculated as well. For each module, genes positively or negatively correlated to
the eigengene were separated into two submodules, according to signs of their memberships.
Negative submodules are denoted by an extra minus sign.
Submodules of genes obtained from WGCNA were uploaded to CTen for detection of
cell enrichments [64]. Genes from each module were compared with CTen’s gene marker
database. Enrichment scores were computed as −log10(p-value) using p-value from Fisher’s
exact test. When more than one submodule was annotated by the same cell subset, the
submodule with the highest enrichment score was chosen to represent this cell type.
3.2.6 Comparison between Estimated Cell Quantities and Flow Cytometry
Data
To explore the accuracy of each algorithm, we calculated R2 and normalized mean squared
error (NMSE) by comparing normalized predictions with processed cell counts from flow






where x is a vector of normalized predictions, and y is a vector of processed cell counts.
Although animals used for flow cytometry are not the same as those for microarray analysis,
mean values of both predicted and measured cell quantities are used to account for errors
due to diversity of animal samples for all comparisons.
For MLLSR and CIBERSORT, log fold change of estimated cell fractions at each time
point versus hour 0 was calculated and compared with log fold change of cell counts to
compute R2 and NMSE scores. The total number of all cells in the lung tissue is not available
because large cells (e.g., epithelial cells) were filtered before cell sorting. We assumed the
total number of cells did not significantly change in the seven days following infection (proof
shown in Figure 18). Therefore, the log fold change of estimated cell fractions (a test sample
vs mock sample) should approximately equal to the log fold change of cell counts. Because
the physical meaning of the output from DCQ is unclear, we compared it with three kinds
of measurement: (i) log fold change of cell counts, (ii) change of cell counts, and (iii) change
of normalized cell counts (the cell number of a cell type divided by the number of total
live cells). The predicted relative cell quantities from DCQ for more than 200 cell subsets
were summed up according to the annotations of its immune cell compendium. For CTen,
the expression pattern of a gene marker is assumed correlated to the dynamic change of
the referring cell type, and eigengene profiles were normalized then compared to cell count
data. The eigengene profiles of the chosen modules were scaled as 0–1, and the profiles from
negative submodules were multiplied by −1 before scaling. The R2 and NMSE scores were
computed in comparison between the normalized eigengene profiles and log fold change of
cell counts.
3.2.7 Computation of Adjusted Gene Expression and Identification of Signifi-
cant Genes
Based on the linear relation i.e., Equation (1) applied in deconvolution algorithms,
CIBERSORT-adjusted gene expression g was defined as the following:
g = b −A · x̂ , (3.3)
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where A is a n × p matrix of expression intensities of p kinds of pure cells for n genes, b
is a vector of expression intensities in a given sample, and x̂ is a vector of estimated cell
fractions for this sample using CIBERSORT. Similarly, cell count-adjusted gene expression
x̃ was defined as
e = b −A · x̃ , (3.4)
where b and A are the same with the above while x̃ is equal to immune cell counts measured
by FACS divided by the average total number of cells per mouse lung [83]. For each gene
from influenza-infected microarray data, the adjusted gene expression g and e was quantile
normalized and compared with that of mock data per time point per sample cohort by
the R package limma [72], and the FDR was computed. Standard differential expression
(DE) analysis was performed by comparing gene expressions of infected samples to mock
samples per time point per cohort and FDR values were computed. For both methods
(adjusted expression and standard DE), the minimum FDR values among all time points
was utilized to characterize the significance of the associated gene. Genes with FDR values
less than 1 ×10−4 for at least two time points were analyzed by DAVID [41, 42] for functional
annotations.
3.3 Results
3.3.1 Dynamic Change of Immune Cell Quantities Induced by Influenza Infec-
tion
To characterize the accuracy of predictions from the set of deconvolution algorithms, the
number of immune cells in mouse lung at five timepoints (day 0, day 1, day 2, day 3, and
day 7) after influenza virus infection were measured by FACS. The cohorts of H5N1 and
pH1N1-infected animals had higher immune cell counts (Figure 19), which was consistent
with studies of lungs infected with highly pathogenic viruses [54, 55, 56]. Figure 5 shows
the number of select immune cells within the lung overtime (Figure 19 shows the results
for all other immune cell counts measured). Macrophages were significantly infiltrated into
24
the mouse lung after day 2 for all sample cohorts (Figure 5). B cell counts did not increase
significantly from the counts observed in mock animals until day 7 for the sample cohorts of
H1N1 and pH1N1, while for H5N1 the quantity of B cells shows a significant decrease at both
day 2 and day 7. For T cells, the H1N1 cohort exhibited an increase in cell number on day 7,
whereas a large increase occurred much earlier (since day 2) for pH1N1. However, for H5N1
the variation of T cell counts was insignificant. We observe that CD4+ T cells show similar
trends across time: the cell counts did not significantly increase until day 7 for the H1N1 and
pH1N1 cohorts, while the cell counts for H5N1 are relatively stable (Figure 19). Dendritic
cells (DCs) for the cohort of H1N1 are up-regulated at day 7, and for pH1N1 as well as H5N1
the cell counts greatly increased since day 2 (Figure 19). NK cell quantities kept increasing
starting from day 3 for H1N1, and day 2 for pH1N1 and H5N1. These dynamic profiles of
cell counts obtained from FACS were used to evaluate cell count predictions from the four
algorithms.
3.3.2 Cibersort More Accurately Predicts Quantity Changes of T Cells and
Macrophages than MLLSR
As explained above, MLLSR and CIBERSORT utilize expression intensities of pure
cells and cell mixture samples to calculate cell fractions by linear regression. To improve
computational efficiency, they both recommend using expression intensities of user-selected
cell marker genes instead of the whole genome. The major difference between the two
algorithms is the regression tool they use (see Materials and Methods). Here we evaluate
the accuracy of MLLSR and CIBERSORT in predicting the mean cell counts observed in
H1N1, pH1N1 or H5N1-infected lung. Two performance measurements for accuracy were
provided: the R2 values and NMSE. As paired data from the same animal is not available (see
Discussion on data limitations), we evaluate each algorithm’s ability to accurately predict
the mean population observed (Materials and Methods).
MLLSR failed to capture average changes in immune cell populations while CIBERSORT
demonstrates significantly better accuracy (Figure 6). Predicted fractions from MLLSR have
comparatively low R2 values and large NMSE scores for most cell types while CIBERSORT
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has improved R2 and reduced NMSE. MLLSR’s predictions overestimated the fractions of
macrophages to be more than 100% at several time points (Figure 6a). Estimations of
macrophages from CIBERSORT had high R2 values: 0.59, 0.95 and 0.95 for H1N1, pH1N1
and H5N1 respectively, with acceptable NMSE scores (0.59, 0.17, and 0.26), but similar
to MLLSR, we observed that CIBERSORT had a tendency to predict higher macrophage
counts than those measured (Figure 6b). CIBERSORT’s estimations on T cells, activated
CD8+ T cells and DCs (Figures 6b and Figure 20) fit well with cell count data for select
sample cohorts. For example, R2 values of T cells was 0.86 and 0.97 for H1N1 and pH1N1
respectively while that of H5N1 was 0.25 (Figure 6b). When predicting less abundant cell
types, MLLSR is unable to estimate CD4+ T cells and CIBERSORT fails to estimate CD8+
T cells (Figure 21). The R2 values across all cell types and all cohorts for MLLSR was 0.13
and 0.34 for CIBERSORT (Figure 22).
Next, we analyzed the time course trajectories of predicted cell fractions. Although
corresponding cell count data was lacking for the majority of time points which have gene
expression data, the smoothness of the time-course cell quantity curve and the timescales
associated with changes in cell fractions can provide another measurement of inference qual-
ity. Figure 7 displays estimated variation of cell populations across time. We observed that
different from cell counts measured by FACS, predictions from MLLSR and CIBERSORT for
B cells variate dramatically between 0 and 0.03 for at least one sample cohort (Figures 7a,b
and 5). Both algorithms failed to capture the decrease of B cells for H5N1, and predictions
from MLLSR are mostly unchanged throughout the seven-day time frame. The increase of
estimated macrophage fractions predicted using MLLSR and CIBERSORT is minimized for
the H1N1 cohort than that of pH1N1 and H5N1, which is consistent with cell count data
(Figures 7a,b and 5). However, the estimations for pH1N1 by MLLSR reached a peak at day
2 and then decreased, and the estimated cell fractions of macrophage for H5N1 showed a
quick increase and stayed at a high level beginning at day 1. All of these disagreed with cell
count data (Figure 5). CIBERSORT’s performance in predicting macrophage cell counts is
slightly improved relative to MLLSR as it better estimates the increase of macrophages for
H5N1. For T cells, MLLSR and CIBERSORT accurately predict the increase of T cells for
the H1N1 and pH1N1 cohorts, including that pH1N1 cohort has the highest increase among
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all cohorts, while they both fail to predict the steady behavior of H5N1 (Figures 7a,b and
5). For other immune cell types, MLLSR estimates DCs to be almost unvaried and close to
zero across the time points sampled for H1N1 (Figure 23). It also estimated CD4+ T cells
and NK cells to be zero for almost all time points of all cohorts (Figure 23). Although this
was corrected in predictions by CIBERSORT (Figure 24), both MLLSR and CIBERSORT
cannot capture the rapid increase of DCs for the pH1N1 cohort. In general, CIBERSORT
was more sensitive to the dynamic changes of immune cell quantities using gene expression
profiles than that of MLLSR, and predicted time-course cell fractions from CIBERSORT
were smoother than those of MLLSR.
3.3.3 DCQ Correctly Predicts Relative Cell Quantities of B Cells and
Macrophages for the pH1N1 and H5N1 Cohorts
DCQ assumes that there is a linear relation between gene expressions and cell quantities
in the same way as MLLSR and CIBERSORT, though it differs from them in three ways:
(i) the input data were prepared by comparing a test sample to a reference sample, and the
output was the relative change in cell quantities instead of the actual cell proportions in
the sample; (ii) DCQ depends on its built-in immune cell compendium for regression and
thus lacks flexibility; (iii) relative cell quantities were predicted using elastic net regulation
(See Materials and Methods and Figure 4b). Since DCQ predicts the relative change of cell
quantity, we compare the estimated relative cell quantities with FACS-measured cell count
data that are preprocessed in three different ways (Materials and Methods). We found that
adjusting the cell counts by the total live number of cells provided the best fits when using
DCQ (Figure 22). The following results (including R2 and NMSE values) were based on this
comparison.
Capable of predicting a variety of immune cell populations, DCQ performs well on subsets
of the sample cohorts. As shown in Figure 8, its predictions of B cells show high R2 values
of 0.84 and 0.92 for the pH1N1 and H5N1 cohorts (NMSE = 0.19 and 0.12, respectively).
However, the R2 for H1N1 was 0.16 (NMSE = 1.34). For macrophages, the estimated relative
cell quantities agree well with normalized cell counts (especially for pH1N1, R2 = 0.98, NMSE
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= 0.11), while the estimations of H1N1 have lower accuracy (R2 = 0.46, NMSE = 0.63).
Analogous to MLLSR and CIBERSORT, DCQ also excessively estimates the quantities of
macrophages for the H5N1 cohort (Figure 25). Regarding less abundant cell types such as
natural killer T cells (NKT cells), DCQ was unable to correctly quantify its change of cell
quantities using lung tissue microarray data. The overall R2 value calculated by comparing
DCQ’s estimations to normalized cell count data was 0.32 for all sample cohorts.
Then we assessed DCQ’s estimations in the time course using the trend in cell quantity
variation. DCQ successfully captures the observed decrease in B cells around day 2 in H5N1
but fails to detect the increase at day 7 for the H1N1 and pH1N1 cohorts (Figures 7c and 5).
For macrophages, DCQ outperforms CIBERSORT and accurately predicts the continuous
increase starting from day 2 for the pH1N1 and H5N1 samples (with the exception of day
7 of H5N1). The stable behavior observed in T cell quantities is correctly predicted for the
H5N1 cohort, while the rising accumulation of T cells after day 2 in pH1N1 samples is not
captured. Additionally, DCQ failed to predict the apparent increase of neutrophils beginning
at day 2 for H5N1 and the behavior of DCs for any sample cohort (Figures 19 and 26). In
conclusion, DCQ is an effective tool for predicting select immune cell subsets and does not
guarantee good performance for all samples.
3.3.4 CTen Shows High Accuracy When Predicting Dynamic Changes in
Macrophages and Neutrophils for All Sample Cohorts
CTen, different from the aforementioned algorithms, did not predict cell quantities by
linear regression. Instead, the approach suggests clustering the gene expression data and
using overlap/enrichment to identify significant associations between clusters of genes and
cell types. Here, we employed WGCNA to cluster genes with highly correlated expression
[82]. The eigengene (the first principle component) of each cluster was then used to quantify
the mean change in the cell counts. The normalized eigengene profiles were not expected
to have the same magnitude as cell count data, but NMSE scores are still provided as a
reference with R2 values.
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CTen shows consistent performance among samples for most cell types tested. It per-
formed well on all sample cohorts for macrophages and neutrophils. Normalized eigengene
profiles of macrophages for each cohort show high R2 values compared to measured cell counts
(Figure 8): that of the H1N1 cohort is 0.84 (NMSE = 0.59), pH1N1 was 0.88 (NMSE = 8.89),
and H5N1 was 0.80 (NMSE = 5.96). CTen’s estimations for neutrophils outperform DCQ
with the H1N1 cohort R2 = 0.70 (NMSE = 0.40), pH1N1 cohort R2 = 0.96 (NMSE = 3.99),
and H5N1 cohort R2 = 0.86 (NMSE = 3.65). The R2 values for H1N1, pH1N1 and H5N1
in NK cells were 0.59, 0.85, and 0.51, respectively, and in DCs were 0.41, 0.86, and 0.56,
respectively (Figure 27). While the estimations for NK cells and DCs have relatively lower
R2 values, no cohort returns an extremely poor R2 value. However, the normalized eigengene
profiles of B cells did not fit well with cell count data (Figure 8), with an R2 value of 0.03 for
H1N1 (NMSE = 1.18), 0.52 for pH1N1 (NMSE = 0.68) and 0.40 for H5N1 (NMSE = 5.78).
The R2 value of CTen’s predictions across all samples was around 0.37, which was the highest
of all four algorithms.
The trend in cell quantity change predicted by CTen aligned with FACS data for select
cell types. CTen successfully captured the increase of macrophages at days 2 and 7 for the
H1N1 cohort, as well as the increase at days 2 and 3 followed by the decrease at day 7 for
H5N1 (Figure 7d). Within the pH1N1 cohort, the macrophage quantities were predicted to
reach a peak before day 3 followed by a slight decrease, a trend which disagrees with cell
count data. For neutrophils, CTen correctly estimated the increase at days 2 and 3 followed
by a slight decrease at day 7 for pH1N1, and the constant increase for H5N1 though the
estimated decrease at day 7 was inaccurate (Figure 28). For the H1N1 cohort, the increase of
neutrophil quantities was overestimated compared to FACS data. Additionally, CTen vastly
improved predictions of dynamic changes in NK cells and DCs. Predicted dynamic changes
in CD4+ T cells were the same with those in CD8+ T cells as shown in Figure 7d. Based on
measured cell counts, the quantities of both cell types did vary at a consistent pace (Figure
5), while the variation was not consistent with what CTen predicts. For example, CD4+ T
cells and CD8+ T cells are relatively constant across time for the H5N1 cohort where CTen’s
predictions show more deviation.
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3.3.5 Improved Disease-Associated Gene Identification by Adjusting for Cellu-
lar Composition
One of the most important applications of deconvolution was to remove gene transcript
count changes due to cell count changes, which should improve identification of gene ex-
pression activity associated more specifically with the disease being studied. Transcriptional
profiles of diseased tissue varied over time as a result of both the fluctuation of immune
cell populations (such as infiltration of macrophages and neutrophils) and the changes of
the gene regulatory networks (activation or repression of certain genes). Based on this as-
sumption, we demonstrated that deconvolution can be combined with statistical analysis
to improve identification of disease-associated genes (see Materials and Methods). Briefly,
changes in transcript levels due to changes in the cellular composition of the tissue were
subtracted from the gene expression data. The resulting gene expression, represented by
g (adjusted by predictions from CIBERSORT) or e (adjusted by cell counts from FACS),
was then analyzed with established microarray statistical tools (e.g., “limma” [72]) to de-
termine significant genes. The FDR values and associated ranks of genes generated using
this adjusted gene expression were compared to those obtained through standard differential
expression (DE) analysis of the unadjusted data.
Adjusted gene expression, based on either inference by CIBERSORT (i.e., g) or measured
cell counts (i.e., e), largely improved FDR values and ranking for genes involved in influenza
infection and the anti-viral immune response. Among the top 10 ranked genes obtained
by sorting FDR values calculated from adjusted gene expression g , Psme1 was the most
significant gene for all three sample cohorts (as shown in Figure 9). Srp14 is ranked 7th and
9th for the H1N1 and pH1N1 cohorts, respectively (ranked 16532th for H5N1). The human
PSME1 protein interacts with influenza A virus protein neuraminidase (NA) according to
the protein-protein interaction (PPI) database VirHostNet2 [84]. The human SRP14 protein
interacts with influenza nucleoprotein (NP), polymerase acidic protein (PA), non-structural
protein 1 (NS1), polymerase basic protein 2 (PB2), RNA-directed RNA polymerase catalytic
subunit (PB1), hemagglutinin (HA), NA, and the matrix protein 1 (M1) [84]. Sqstm1,
Mapkapk2, and Lamtor2 are also found in the 20 most significant genes for different cohorts
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(Figure 9), all of which are well known for being associated with the NF-κB signaling [85]
and MAPK/ERK pathways [86, 87]. However, in the standard DE analysis based on original
gene expression, Psme1 is ranked 456th, 1353th and 1145th for H1N1, pH1N1 and H5N1,
respectively. Srp14 is not included in the top 1000 genes with much higher FDR values.
For Sqstm1, Mapkapk2, and Lamtor2, genes which are considered important in adjusted
gene expression analysis, their rank is significantly lower than those from adjusted gene
expression (Figure 9). Instead, Cxcl9, the chemokine that attracts NK cells and T cells [88],
is ranked higher using unadjusted gene expression data (2nd for the pH1N1 cohort). For
significant genes obtained from adjusted gene expression e , which is computed based on cell
counts measured by FACS, Plac8 is ranked 1st, 97th and 22nd for the H1N1, pH1N1 and
H5N1 cohorts, respectively, whose human protein interacts with PB1 [84]. Nudc is ranked
7th and 288th for the pH1N1 and H5N1 cohorts (12499th for the H1N1 cohort). The human
NUDC protein interacts with M1, HA, and NA proteins [84]. Similar to the adjusted gene
expression g , we find Sqstm1 and Mapk7 among the top 10 genes. Furthermore, Irg1 is
ranked 4th and 34th for pH1N1 and H5N1 cohorts, respectively. This gene is considered
significant through standard differential analysis while regarded as rather insignificant by
gene expression adjusted by predictions from CIBERSORT with FDR values greater than
0.01 for all sample cohorts. This indicates that using adjusted gene expression values is better
isolating gene expression associated directly with virus replication while using unadjusted
expression is isolating immune response events induced by the infection while the ability of
identifying disease-associated genes depends on the approach of adjustment.
When considering functional enrichment analysis of DE gene sets, unadjusted expres-
sion identified several key virus-infection-associated processes while adjusted gene expres-
sion filters out part of the annotations associated with inflammatory response. For example,
significant genes (FDR < 10−4 for at least two timepoints, see Materials and Methods)
obtained from adjusted gene expression g for the pH1N1 cohort are enriched in antigen
processing and presentation, 4-iron-4-sulfur cluster binding and small GTP-binding protein
domain. The H1N1 and H5N1 cohorts are enriched in Ras-association, endoplasmic retic-
ulum (ER), protein transport and proteasome. All three sample cohorts were enriched in
cadherin binding involved in cell-cell adhesion, ribosomal protein. In contrast, significant
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genes from standard DE analysis were associated with annotations related to response to
virus and 2-5-oligoadenylate synthetase for all sample cohorts. Both the pH1N1 and H5N1
cohorts were highly enriched in chemotaxis, cytokine activity, cellular response to interferon-
gamma and cell cycle. For significant genes calculated from adjusted gene expression e , their
enriched functional annotations were similar to those for standard DE. All sample cohorts
were enriched in 2′-5′-oligoadenylate synthase, innate immune response, and both pH1N1
and H5N1 cohorts are enriched in cellular response to interferon-gamma. The H1N1 cohort
is also related to RNA binding and regulation of transcription, and the pH1N1 is associated
with antigen processing and presentation as well as GTP binding.
3.4 Conclusion and Discussion
In this work, we applied four deconvolution algorithms to microarray data from mouse
lung tissue infected by the influenza virus and tested their accuracy on predicting either
absolute or relative changes in cell counts. Most algorithms predict well on several cell types
for select sample cohorts except MLLSR, which is unsuccessful in the majority cohorts/cell
types tested and has the lowest R2 value. We utilized the estimated cell quantities to
modify differential expression analysis and demonstrated that the adjusted gene expression
largely improves the statistical significance of disease-associated genes and the efficiency of
discovering key factors.
The first major caveat of the presented work is that the data is unpaired. Ideally,
the gene expression and cell count data would come from the same animals. But in mice
studies, tissue quantity is limited, and it is very common for pathology studies to have
unpaired data (i.e., data from different animals) [29, 89, 90, 91]. We justify our approach
here of evaluating the ability of the algorithms to predict the mean cell counts (or mean
change in cell counts) as the animals used for lung gene expression and those for lung cell
counts were infected with the same viruses, at the same initial loads, in the same laboratory
and demonstrated the same symptoms and disease characteristics over time (e.g., weight
loss, general lethargy and death due to infection were consistent [29]). Furthermore, the
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mice having the same genetic background were housed in the same facilities and treated
in the same manner during the experiments. Future work will focus on collecting paired
gene expression and cell count data to provide a more thorough analysis of deconvolution
algorithm’s predictive performance. Yet, this work is still highly significant as whole genome
gene expression analysis is a common and established tool to characterize disease-associated
gene expression, and the findings summarized below strongly suggest that changes in tissue
cellular composition must be addressed to improve prioritization of disease-associated gene
candidates.
Based on the analysis of microarray data of influenza-infected mouse lungs, we find that
the clustering-based algorithm, CTen, provides the most accurate cell count estimates. This
improved predictive performance is likely due to the ability of CTen to infer across time
points, whereas MLLSR, CIBERSORT and DCQ compute each time point independently.
In addition, the regression-based tools analyzed here require much more reference data than
CTen. These problems raise additional questions about the ability of select regression-based
algorithms to infer accurately when applied to tissue samples, even though they demon-
strated reasonable performance in the deconvolution of samples comprised of only 3 or 4 cell
populations [67, 70]. Therefore, future research on cell count inference of time-course tran-
scriptional profiles should consider either the more advanced clustering technologies (e.g.,
t-SNE [92]), or the models in the regression algorithms should be modified to account for
time-course dynamics.
The regression-based algorithms can be utilized to infer cell quantities when applied to
data from single time points and if the suitable reference data is available. This study finds
that CIBERSORT provides more accurate predictions than MLLSR or DCQ for expression
profiles sampled at a single time point. We also find that the inference accuracy of the tested
algorithms is independent of the scale of the cell count data for CIBERSORT, MLLSR and
CTen, but DCQ shows a significant association with the scale of the data having an R2 value
of 0.26 (as shown in Figure 29), suggesting that the accuracy of DCQ is biased to larger cell
populations.
Finally, we demonstrate that adjusting gene expression due to changing cell popula-
tions within the tissue improves the identification of disease-associated genes. However, the
33
discovery of influenza virus-associated genes was improved at the cost of weakening the iden-
tification of biological functions. A possible explanation is that we utilized a strict cutoff of
FDR values for all sample cohorts (FDR < 10−4 for at least two timepoints) in order to limit
the number of genes for functional annotation analysis. Another important reason may be
that the adjustment due to changing cellular composition was moderately accurate since the
estimated cell fractions have an overall R2 value no larger than 0.4 when compared with mea-
sured cell counts. But despite the limitation, our study emphasizes that the adjustment of
cell composition applied to transcriptomic data improves identification of meaningful genes
which could be used as potential drug targets. Further improvement of deconvolution algo-
rithms will greatly advance the systems biology and bioinformatics communities’ ability to
accurately model complex disease in tissue and improve the discovery of disease-associated
genes.
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Figure 5: Cell counts of B cells, macrophages, and T cells in mouse lungs after infection by
either H1N1, pH1N1 or H5N1 virus. Day 0 data are from uninfected, control animals. *
Animals infected by H5N1 died before day 7.
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Figure 6: Log fold change (virus infection versus mock) of estimated cell fractions by modified
linear least-squares regression (LLSR) (a) and cell-type identification by estimating relative
subsets of RNA transcripts (CIBERSORT) (b) in comparison with log fold change of cell
counts measured by fluorescence-activated cell sorting (FACS) for B cells, macrophages and
T cells. Concordance is characterized by R2 and normalized mean squared error (NMSE)
values. The black line is y = x while the grey dashed line is regression.
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Figure 7: Estimated cell quantities of B cells, macrophages and T cells across time obtained
using (a) MLLSR, (b) CIBERSORT, (c) digital cell quantification (DCQ), and (d) cell type
enrichment (CTen). There were three samples per time point. Error bars depict the standard
deviation of the estimate.
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Figure 8: Two measurements for the accuracy of predicted cell quantities. Log fold changes
of estimated cell fractions from MLLSR or CIBERSORT are compared with log fold changes
of cell counts at the same time point per virus strain to compute R2 (a) and NMSE (b).
Similarly, R2 (a) and NMSE (b) values for DCQ are calculated as estimated relative cell
quantities versus change of normalized cell counts. R2 (a) and NMSE (b) of CTen’s predic-
tions are calculated as eigengene profiles against log fold changes of cell counts.
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Figure 9: Ranking and false discovery rate (FDR) values of significant genes from calculating
adjusted gene expressions and standard differential expression (DE) analysis.
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4.0 Network Insights into Improving Drug Target Inference Algorithms
4.1 Introduction
The innovation of treatments for diseases remains a challenging task [93, 6, 94, 95, 96, 21].
The efficiency of pharmaceutical research and development (R&D), quantified by the number
of new drugs per billion US dollars spent, dramatically declined from 1950 to 2010 [6]. A large
group of drug candidates fail in clinical trials because they are not effective or safe in humans
[6, 96, 97, 98, 12]. A major reason is that the systematic effects of drug candidates are not
well studied or modelled in the drug discovery process, and a better understanding of their
mechanisms of action (MoA) can help improve the efficiency of drug R&D [6, 99, 100, 101].
Two types of computational approaches have been reported to study MoAs of drugs
by modeling high-throughput biological data: comparative analysis and network-based al-
gorithms [102, 31]. Comparative analysis approaches, such as the Connectivity Map [103],
have been used to predict molecular targets of drugs and assist in drug repurposing [103,
104, 105, 106, 107, 108]. They utilize expression profiles as drug signatures and compare
with drugs having known targets, assuming that drugs with high similarities share the same
targets. These approaches much rely on prior knowledge of drugs, thus have limitations in
predicting de novo targets.
Network-based algorithms predict drug or disease targets by combining network infor-
mation and transcriptomic data [31, 109, 30, 110, 111, 112, 113, 114]. Two recent represen-
tatives, DeMAND [30] and ProTINA [31], model the systemic dysregulation of regulatory
network caused by a drug treatment, connecting molecular interactions with differential ex-
pression (DE). The regulatory network is generated by using protein-protein interactions
(PPIs) and protein-gene interactions (PGIs) obtained from self-curated or public databases,
such as STRING [115] and CellNet [116]. Similar to what has been reported by Noh et al
[31], our preliminary research showed that ProTINA outperforms DeMAND when tested by
the same gene expression and network datasets (p-value < 0.0002, Figure 30). Therefore, in
this work, we focused on studying ProTINA’s performance.
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For ProTINA, a regulatory network, directing from proteins or transcription factors
(TFs) to regulated genes, is generated from input PPIs and PGIs based on certain rules
(Figure 10) [31]. The assumption is that the log fold change (LFC) of a gene is the linear
combination of the LFCs of all proteins and TFs that regulate it. The weights are computed
by linear regression methods and then integrated into a score for each regulator, a protein
or a TF. Different from DeMAND, ProTINA may result in negative or positive scores,
representing attenuation or enhancement, respectively. Regulators of larger magnitudes are
more likely to be targets (red nodes in Figure 10). Showing promising results in predicting
targets for in vitro datasets, DeMAND and ProTINA have provided a new direction in
identifying drug targets and toxicity [31, 30].
However, as target inference algorithms become more complicated, it is unclear what
roles gene expression and network data play. For predictions of perturbation patterns by
biochemical models, network topology shows more impact on prediction accuracy than any
other types of biological data, such as kinetic parameters [32]. Several studies have shown
that proteins associated with disease and proteins that are drug targets have significantly
different positions within biological networks [117, 118, 119, 120]. For target inference al-
gorithms, it remains an open question as to which kind of biological data most affects the
accuracy. Furthermore, algorithms can infer drug targets in a cell/tissue type-specific man-
ner [31, 30, 114], and it is unknown how efficient or meaningful cell/tissue type-specific
network data is for target inference. Answering these questions can provide us with insights
into future algorithm improvement.
In this work, we evaluated the impact of gene expression and network data, using the
human B cell microarray data from the DREAM challenge (referred to as DP14) as our
benchmark dataset [121], and introduced a new algorithm to predict drug targets. Firstly,
we found that ProTINA’s scores are mostly determined by network data through permutation
tests on gene expression. Secondly, we tested how the selection of networks affects prediction
accuracy. Surprisingly, the effects of size or cell type are negligible. Next, our analysis
suggested that network betweenness values can accurately predict drug targets. Different
from network degrees, the accuracy is consistent regardless of the network size, and the
performance is comparable with ProTINA.
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Based on these findings, we proposed TREAP as an alternative approach to ProTINA,
which combines the ranks obtained from betweenness values and adjusted p-values to predict
drug targets. Here, we want to highlight the advantages of TREAP compared with other
similar approaches. Firstly, TREAP has consistent performance on different datasets, and
the median area under the receiver operating characteristics (AUROC) values are above
0.800 for all three datasets studied in this work. The median AUROC values are also higher
than ProTINA and DeMAND for the same datasets. Secondly, TREAP is significantly
more time-efficient than most other methods. Moreover, the simplicity and flexibility of the
algorithm makes it more tractable to users who are not experts in systems and network
biology. Thirdly, we chose betweenness values because our analysis showed that compared
with degrees, they are less affected by the change in network size.
4.2 Methodology
4.2.1 Gene Expression Data Used in the Analysis
The microarray data of human Diffuse Large B-Cell Lymphoma (DLBCL) OCI-LY3 cell
line treated with 14 different drugs under diverse doses at 3 time points, 6, 12 and 24 hours
post treatment were obtained from the NCI-DREAM challenge drug synergy dataset, DP14
(GEO accession: GSE51068) [121]. Three samples treated with ‘Aclacinomycin A’ under a
lower dose were dropped due to less significance. The microarray data of human liver cell
line HepG2 treated with 62 genotoxic or non-genotoxic chemicals at 12, 24 and 48 hours
post treatment were obtained from literature, referred to as HepG2 in this work (GEO
accession: GSE28878) [122]. The microarray data of mouse pancreatic cells treated with 29
chromatin-targeting compounds were also obtained from GEO database, referred to as MP
(GEO accession: GSE36379) [123]. For all three datasets, raw data were normalized using
the RMA function from the “affy” R package [124]. The log2 fold change (LFC) values and
Benjamini–Hochberg adjusted p-values (adjusted p-values) were calculated by the “limma”
R package [72]. Probes were mapped to gene symbols by using the “hgu219.db” R package
44
[125] for human microarray data and “moe430a.db” [126] for mouse data. Those with the
lowest average BH-adjusted p-value across all samples were chosen when multiple probes
were mapped to the same gene.
4.2.2 Networks Used in the Analysis and Calculation of Topological Features
Human or mouse PPIs and their associated confidence scores were obtained from the
STRING database [115]. Interactions with experimental proof or from curated databases
(the channels of ‘experiments’ and ‘databases’) were extracted. Interactions transferred from
other species or duplicated entries were excluded. Subnetworks were obtained by applying
thresholds ranging from 0.4 to 0.9 to the PPI network, referred to as PPI04, PPI05, PPI06,
PPI07, PPI08 and PPI09, respectively in this paper.
Human PGIs and their confidence scores were obtained from the Regulatory Circuits,
a database of predicted, cell/tissue type-specific PGIs [127]. PGI networks of 8 different
cell/tissue types were studied in this analysis: ‘lymphocytes of B lineage’, ‘lymphocytes’,
‘lymphoma’, ‘myeloid leukocytes’, ‘lung’, ‘heart’, ‘epithelial cells’ and ‘hepatocellular car-
cinoma cell line’. The network of ‘lymphocytes of B lineage’ were predicted by samples
including those from DLBCL, the same cell line with DP14 [127], thus was chosen as a
reference for analysis of DP14. PGI subnetworks for each cell/tissue type, namely PGI05,
PGI10, PGI15 and PGI20, were obtained by thresholds ranging from 0.05 to 0.20, respec-
tively. Mouse PGIs were compiled from two manually curated databases of transcriptional
regulatory networks: TRRUST (version 2) [128] and RegNetwork [129]. These interactions
are not cell/tissue type-specific, and no threshold was applied to them prior to analysis of
MP.
Degree or betweenness values were calculated by the “igraph” R package [130]. PPIs
or the combination of PPIs and PGIs (PPI+PGI) were treated as undirected graphs, while
PGIs were treated as directed graphs.
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4.2.3 Reference Drug Targets
The reference targets of each chemical were extracted from STITCH database (version
5.0) [131, 132] for analyses of DP14, HepG2 and MP. Only targets with experimental proof
or from curated databases were collected.
4.2.4 Prediction of Drug Targets by ProTINA
LFC values, PPI and PGI subnetworks were analyzed by “protina” R package [31]. Slope
matrices of each time point were calculated following the user manual. For samples with only
two timepoints, control samples served as 0hr post treatment to calculate associated slope
matrices. Samples from different doses for the same drug were treated as separate groups.
4.2.5 Prediction of Drug Targets by TREAP
For target prediction by TREAP, the assumption is that genes with high betweenness
values or low adjusted p-values are more likely to be drug targets. There are three steps
for this algorithm. The first step is to calculate PPI+PGI betweenness values and obtain
adjusted p-values from DE analysis. For gene expression profiles with multiple timepoints,
DE analysis can be performed per time point or across all timepoints. The second step is to
calculate the ranks of genes by sorting betweenness values and adjusted p-values, respectively.
Genes with high betweenness values or low adjusted p-values are scored with high ranks.
The third step is to generate final scores by summing up the ranks from both metrics for
each gene. Genes with higher scores are more likely to be targets for associated drugs.
Adjusted p-values and PPI+PGI betweenness values were calculated as explained in the
former sections. Ranks of genes were obtained by sorting betweenness values and adjusted
p-values, respectively, and genes with the same betweenness or adjusted p-value shared the
same rank. Final scores were calculated by summing up the ranks from both metrics for
each gene. In this work, all analyses on TREAP used 0.9 as the threshold for human or
mouse PPIs and 0.20 for human PGIs. No threshold was applied to mouse PGIs.
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4.2.6 Calculation and Comparison of AUROC Values
Area under the receiving operator characteristics (AUROC) values in this paper were
calculated by comparing scored proteins with reference drug targets through the “pROC ” R
package [133]. As ProTINA scores can be positive or negative, the absolute scores were used
to calculate AUROC. The median AUROC across all drugs in each dataset was calculated
to represent accuracy of a whole test. For drugs having more than one doses, the AUROC
values of low doses were excluded. In terms of topological features, degree or betweenness
values were directly used to calculate AUROC values without pre-processing. TREAP scores
were directly used for calculation of AUROC without preprocessing. Difference in any pair
of chosen tests were computed by performing pairwise t-test between their AUROC values.
A p-value less than 0.05 were regarded as significantly different.
4.2.7 Permutation Tests on Gene Expression
The null hypothesis for permutation tests in this work is that the median AUROCs
of randomized gene expression are smaller than that of nonrandomized gene expression,
and the p-values were calculated accordingly. For ProTINA, gene labels for DP14 that
refer to the rows of LFC and associated slope matrices were randomly shuffled for 1000
times. Randomized data were applied to ProTINA under the same network setup, PPI09
and PGI20. For TREAP, gene labels of adjusted p-values for each dataset, namely DP14,
HepG2 and MP were randomly shuffled for 1000 times, respectively, and drug targets were
predicted using PPI09 and PGI20 (for MP no threshold was applied). AUROC and median
values were calculated as explained in the former section.
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4.3 Results
4.3.1 Permutation Tests Show that ProTINA is Predominantly Determined by
Network Data
To understand how much network or gene expression data contribute to ProTINA’s
accuracy, we performed 1000 permutation tests by randomizing the LFC gene expression
values (Materials and Methods). To shorten the computation time on ProTINA, the smallest
PPI and PGI subnetworks (PPI09 and PGI20) were chosen for this analysis (discussed more
in the following section). For prediction scores obtained from ProTINA, the area under the
receiver operating characteristics (AUROC) values were calculated per drug, and the median
AUROC across all drugs is used as a metric for each test.
The median AUROC obtained by nonrandomized LFCs is 0.799. As shown in Figure
11, 220 of 1000 permutation tests have higher median AUROC values than that (one-tailed
p-value = 0.221). Most tests have similar accuracy to the original test. This indicates that
randomizing LFCs does not diminish ProTINA’s accuracy significantly, therefore, network
data determines most of ProTINA’s performance.
4.3.2 Selection of Networks Has Limited Effects in the Prediction Accuracy of
ProTINA
Next, we studied how the selection of PPIs and PGIs affects target inference accuracy.
PPI and PGI subnetworks of different sizes or cell/tissue types were tested using the same
gene expression data from DP14 (Materials and Methods). Similar to permutation tests, the
median AUROC represents the accuracy for each PPI-PGI combination.
In total, 24 PPI-PGI combinations of different sizes were tested on ProTINA. As shown
in Figure 12a, ProTINA favors small PPI and large PGI subnetworks. The combination
of PPI09 and PGI05 shows the highest accuracy, and its median AUROC is 0.821. As the
threshold increases from 0.4 to 0.9, the number of interactions in PPI subnetwork ranges
from 380375 to 281357 (Figure 31), and the median AUROC increases for most tests. For
example, the median AUROC increases from 0.785 (PPI04) to 0.811 (PPI09) for analyses
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Figure 10: An overview of ProTINA algorithm. Each node refers to a transcription factor
(TF), a non-TF protein (P) or a gene (G). Arrows present the directions of interactions or
edges. The significance of an edge or protein (including TFs) is color coded, where red refers
to high significance while blue refers to low significance.
Figure 11: 1000 Permutation tests were performed by randomizing the gene expression
and calculating the median AUROCs. The blue vertical line refers to the median AUROC
obtained by nonrandomized gene expression.
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under PGI10. But there are PPI subnetworks that do not follow this trend. Under PGI05,
PPI05 shows lower median AUROC than PPI04 (0.784 and 0.796, respectively). For PGI
subnetworks, as the number of interactions range from 123394 to 5932 (Figure 31), the
median AUROC shows an opposite trend to that of PPI subnetworks (Figure 12a). An
example is that the median AUROC decreases from 0.821 (PGI05) to 0.785 (PGI20) when
using PPI09. Most tests show a consistent trend except for those using PPI05. A possible
reason is that new proteins and associated interactions are included in the network as the
threshold for PGIs changes from 0.05 to 0.10. So that the network topology is changed, and
predictions from ProTINA are affected accordingly.
However, median AUROC values vary in a small range while the size of PPI or PGI
subnetworks changes significantly (Figure 12a, 12b and Figure 32). The highest and lowest
median AUROC values for ProTINA are 0.821 and 0.753, with a difference less than 0.1
(Figure 12b). In addition, most of these differences are insignificant. When comparing with
the test using PPI09 and PGI20, none of the 24 tests are significant in AUROC values
(p-value > 0.05 for all tests), although the combination of PPI04 and PGI15 has resulted
in a pairwise p-value of 0.057. Furthermore, we studied the effects on standard deviations
(SDs) of AUROC values across 12 drugs for each test. All of them maintain at a low level
below 0.13. In summary, we conclude that the size of networks has limited effects on the
prediction accuracy of ProTINA, while small PPI and large PGI networks tend to improve
the accuracy.
To analyze the performance of cell/tissue type-specific networks, 28 tests using PGIs
from 7 cell/tissue types were performed on ProTINA using the same PPI subnetwork, PPI09.
Most tests counterintuitively show similar median AUROC values regardless of cell/tissue
types (Figure 12c, Figure 33). In theory, the PGI subnetworks for immune cells should have
higher accuracy than non-immune cell types, and those for ‘lymphocytes of B cell lineage’
should outperform other immune cells. This is because that samples from DLBCL, the same
cell line with DP14, were used to predict the interactions for ‘lymphocytes of B lineage’ [127]
(Materials and Methods). However, using the AUROC values from PGI20 for ‘lymphocytes
of B cell lineage’ as a reference, no other cell/tissue types are significantly different (pairwise
p-values > 0.05 for all) under the same network setup. In conclusion, we have shown that
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Figure 12: Prediction accuracy of ProTINA using networks of different sizes or cell/tissue
types. (a) PPI or PGI subnetworks of different sizes were tested on ProTINA to predict
targets for DP14. The axes refer to the confidence thresholds for PPI (x axis) and PGI (y
axis) subnetworks, and the median AUROC values are the metric for prediction accuracy.
Among all PPI-PGI subnetwork combinations, PPI09-PPI05 and PPI04-PPI20 have the
highest and lowest accuracy in terms of median AUROC values, respectively. Panel (b)
shows the boxplot of these two groups. Each dot represents the AUROC of a drug. (c) PGI
subnetworks of 7 cell/tissue types were applied to ProTINA for target prediction.
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the selection of PPIs or PGIs in terms of either the size or cell/tissue type is not the key
factor to prediction accuracy of ProTINA.
4.3.3 Topological Features Have Similar Prediction Accuracy to ProTINA, and
the Protein Betweenness Outperforms Degree
Our findings have shown that ProTINA depends on network topology more than gene
expression, and that it has consistent performance regardless of the network size or the
cell/tissue type the network represents. These suggest that ProTINA is probably determined
by some network topological feature that remains relatively stable across different PPI or
PGI subnetworks, such as protein degree or betweenness. The degree of a protein is the
number of proteins/genes with which it interacts, while the betweenness is a measure of
bottleneckedness, e.g. the amount of information flowing through the proteins that connect
the rest of the network. Analyses of these features and their effects on drug target prediction
may provide meaningful insights on improving prediction accuracy.
To test our hypotheses, we studied degree and betweenness values for PPIs, PGIs and
PPI-PGI combinations (referred to as PPI+PGI in the following text). Firstly, for PPIs, we
compared scores obtained from ProTINA (using PPI09 and PGI20) with their associated
protein degrees or betweenness values in PPI09 for each drug. The majority of the drugs
show a weak but evident correlation between absolute ProTINA scores and protein degrees,
however, the correlation for betweenness is much lower (Table 3). For instance, the correla-
tion coefficient is 0.211 for ‘Rapamycin’ (Figure 13a), while the correlation of betweenness
values is smaller than that of degrees, which is 0.085 for the same drug (Figure 13b). Notice
that a large portion of the top 100 proteins scored by ProTINA (red points in Figure 13a,
b) lie in the group of high degree or betweenness values.
We next tried to predict drug targets by using PPI degree or betweenness values without
considering gene expression or PGIs. The assumption is that proteins with higher degree or
betweenness values are more likely to be targets. As shown in Figure 13c, the median AUROC
values for PPI degree or betweenness values are close to those for ProTINA. What’s more,
betweenness values perform better than degrees. The highest and lowest median AUROC
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Figure 13: (a) Degree or (b) betweenness values of proteins in PPIs were compared with
associated ProTINA scores for ‘Rapamycin’. The correlation coefficient is 0.211 for absolute
ProTINA scores and degrees, and that for betweenness values is 0.085. Red points refer to
the top 100 proteins scored by ProTINA. (c) The degree and betweenness values were used
to predict drug targets assuming higher scores are more likely to be targets. Each point
shows the median AUROC value and the number of proteins under a PPI threshold. For
reference, the grey dashed line refers to the highest median AUROC achieved by ProTINA,
which was obtained by using PPI09 and PGI05.
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values for degrees are 0.814 and 0.727 (Figure 13c), and those for betweenness values are
0.866 and 0.800, even higher than associated median AUROC values for ProTINA under
the same network setup. As the size of PPI subnetworks shrinks, the median AUROCs
for degrees decreases accordingly (Figure 13c), with a correlation coefficient value of -0.950
between the medians and thresholds. While the decrease of network size also diminishes
the accuracy of betweenness, the median AUROCs remain higher than those of degrees and
decrease relatively slower.
Secondly, the degree and betweenness values of PGI subnetworks were also compared
with associated ProTINA scores, however, there are no clear trends between them (Table
3). In addition, drug target prediction based on PGI degree or betweenness values are not
comparable with that by PPI topological features (Figure 34). This might be related to the
limited amount of PGI interactions.
Lastly, we calculated topological features for PPI+PGI and compared them with ProTINA
scores. As expected, they show the same trend with PPIs (Table 3). The correlation coeffi-
cient between degrees and ProTINA scores is 0.208 for ‘Rapamycin’, while that for between-
ness values is 0.079 (Figure 14a, b).
Predicting drug targets by PPI+PGI degree or betweenness values results in higher
median AUROC values than those for PPIs. In addition, for all thresholds of PPIs or
PGIs applied to this analysis, betweenness values outperform degrees. The accuracy for
PPI+PGI degrees ranges from 0.833 to 0.733 in terms of median AUROC values, and that
for betweenness values ranges from 0.878 to 0.782 (Figure 14c). As the size of PPI or PGI
subnetworks decreases, the median AUROC values for PPI+PGI degrees also decreases.
PPI+PGI betweenness values have the same behavior as the size of PPIs changes, while for
PGIs the trend is less evident. PGI10 has the best performance in parallel comparisons. In
summary, betweenness values well predict drug targets and show even higher accuracy than
ProTINA.
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Figure 14: (a) PPI+PGI degree or (b) betweenness values were compared with associated
ProTINA scores for ‘Rapamycin’. The correlation coefficient for absolute ProTINA scores
versus degrees and absolute ProTINA scores versus betweenness values is 0.208 and 0.079,
respectively. Red points refer to the top 100 proteins scored by ProTINA. (c) The degree and
betweenness values were used as measures to predict drug targets, and the median AUROC
values were calculated for each prediction. The axes refer to the confidence thresholds for
PPI (x axis) and PGI (y axis) subnetworks.
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4.3.4 Missing Information in Network Topology Can be Covered by Differential
Expression
Topological features, degree or betweenness values, have shown high prediction accuracy
without taking gene expression into account. Our permutation tests have also indicated that
network data has more effects in ProTINA’s performance than gene expression data. What’s
more, ProTINA has much better performance than differential expression (DE) analysis on
drug target prediction according to prior research [31]. All of the above has raised a question
about whether gene expression data can help to predict drug targets. To address this concern,
we compared DE analysis (adjusted p-values, Materials and Methods) with two other target
prediction methods in terms of their performance on each drug: PPI+PGI betweenness and
ProTINA.
We calculated AUROC values for all three methods using the same network setup, PPI09
and PGI20 (Figure 15). For most drugs, such as ‘Mitomycin C’ or ‘Cycloheximide’, PPI+PGI
betweenness and ProTINA have close AUROC values, and they outperform DE analysis.
Consistent behaviors between ProTINA and PPI+PGI further indicates the impact of net-
work topology on ProTINA’s accuracy. In contrast to these drugs, DE has much higher
prediction accuracy than PPI+PGI or ProTINA for ‘Monastrol’ (the AUROCs are 0.998,
0.771 and 0.555, respectively). This means that DE analysis of gene expression data can
capture information missing in network topology, and that it is necessary to include gene
expression data for drug target inference and improvement of accuracy.
4.3.5 A Novel Algorithm that Combines Network Topology and DE Analysis
for Target Inference
To better combine network topology and DE analysis and improve inference accuracy,
we suggest TREAP (target inference by ranking betweenness values and adjusted p-values)
to predict drug targets (https://github.com/ImmuSystems-Lab/TREAP). There are three
steps for this algorithm. The first step is to calculate PPI+PGI betweenness values and
obtain adjusted p-values from DE analysis. For gene expression profiles with multiple time-
points, DE analysis can be performed per time point or across all timepoints. The second
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Figure 15: AUROC values of each drug obtained from three different methods: differential
expression (DE) analysis by adjusted p-values, betweenness values from the combination of
PPI09 and PGI20 (PPI+PGI) and ProTINA analysis by PPI09 and PGI20.
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step is to calculate the ranks of genes by sorting betweenness values and adjusted p-values,
respectively. Genes with high betweenness values or low adjusted p-values are scored with
high ranks. The third step is to generate final scores by summing up the ranks from both
metrics for each gene. Genes with higher scores are more likely to be targets for associated
drugs.
TREAP was tested by three different gene expression profiles: (i) DP14 [121], (ii) human
HepG2 cells treated with genotoxic or non-genotoxic chemicals, referred to as HepG2 in this
work [122] and (iii) mouse pancreatic cell lines treated with chromatin-targeting compounds,
referred to as MP [123]. Human and mouse PPIs were obtained from STRING [115], and
PGIs were obtained from Regulatory Circuits [127], TRRUST (version 2) [128] and Reg-
Network [129]. AUROCs were calculated by comparing scored genes with known targets for
each test as a measurement of accuracy.
TREAP shows stable performance and maintains high accuracy for all datasets tested
in this study (median AUROCs > 0.800, Figure 16). While TREAP takes significantly
less computation time than ProTINA, it has higher median AUROCs when compared with
ProTINA under the same dataset (Figure 16). For DP14, the median AUROC of TREAP is
0.850, higher than that of ProTINA, 0.799 (p-value = 0.11). Notice that it is also higher than
using PPI+PGI betweenness values alone, which is 0.798. TREAP significantly outperforms
ProTINA in HepG2. The median AUROC is significantly improved from 0.739 to 0.801, with
a p-value of 0.0002. For MP, TREAP and ProTINA have close median AUROCs as 0.806
and 0.799, respectively (p-value = 0.39). By integrating betweenness values and adjusted
p-values to represent both network topology and DE analysis, TREAP is comparable with
and sometimes better than ProTINA in accuracy for all datasets analyzed in this work. In
addition, we performed 1000 permutation tests on TREAP by randomizing the adjusted
p-values for each dataset. Different from ProTINA, TREAP is significant when compared
with permutation tests on the adjusted p-values from DP14, with the one-tailed p-value as
0.007 (Figure 35). For HepG2, the one-tailed p-value is 0.058, while for MP, TREAP is less
significant and shows a one-tailed p-value as 0.314.
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Figure 16: AUROC values of TREAP and ProTINA predictions for different gene expres-
sion profiles: human lymphoma cells (DP14), human liver cancer cells (HepG2) and mouse
pancreatic cells (MP). (p-values = 0.11, 0.0002 and 0.39, respectively)
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4.4 Conclusion and Discussion
Our analyses have shown that, even though ProTINA requires both gene expression and
network data for inputs, network data predominantly determines accuracy of drug target
inference. What’s more, the cell/tissue type or size of a network has limited impact on
ProTINA’s accuracy, while topology, especially the degree value, affects the performance of
ProTINA more.
However, ProTINA has two limitations due to the reliance on network topology alone
and the connection with protein degrees. First, PPIs, a major part of network data, have
a known bias toward protein abundance [119, 134]. It has been reported that interactions
obtained from high-throughput experiments have a correlation between the protein degree
and abundance. Second, we have shown that differential analysis of gene expression data
can uncover meaningful information missing in network topology.
To address these two limitations, we suggested a new algorithm, TREAP, which com-
bines protein betweenness values and adjusted p-values, representing information from both
sources of network topology and DE analysis, to predict drug targets. We chose betweenness
values because they are less sensitive to network sizes and more accurate than degrees in
target prediction. TREAP shows more consistent performance than ProTINA when tested
by different gene expression profiles and maintains a median AUROC above 0.800. In ad-
dition, TREAP takes significantly less computation time than ProTINA, and its simplicity
makes it more tractable to users who are not experts in systems and network biology. It is
also flexible in dealing with samples of limited or multiple timepoints as adjusted p-values
can be calculated per timepoint or across all timepoints based on user’s needs. However,
ProTINA needs at least two timepoints to fully take advantage of the algorithm [31]. Cur-
rently, betweenness values and adjusted p-values are weighted equally for TREAP. Future
work should focus on better balancing both types of data and trying other scoring methods
to improve prediction accuracy.
TREAP is presented here as an alternative approach to ProTINA, but it is worth em-
phasizing advantages specific to each algorithm. As stated above, TREAP is significantly
faster, and the algorithm is not complex, enabling users from several branches of research to
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access the tool and understand the findings. ProTINA, however, is a mechanistically derived
algorithm, which allows users with expertise in computational biology to dive deeper into the
possible mechanisms of a drug’s activity. The accuracy of their predictions is similar when
measured using the AUROC, but the permutation tests presented here suggest that TREAP
is more likely to use drug-specific gene expression to make a more accurate prediction.
TREAP and its derivatives have potential in a variety of applications for drug innovation.
First, it can assist in selection of drug candidates and serve as a preliminary test of the efficacy
or safety by connecting with databases for functional annotations, e.g. Gene Ontology
[135, 136]. Studying predicted targets can help exclude poorly targeting drug candidates or
those causing severe damage to biological systems. Second, the algorithm can be applied to
drug repurposing by exploring published datasets characterizing drug treatments, assuming
that a pair of drugs sharing the same group of predicted targets can be used to treat the
same disease. Last but not the least, the algorithm can help to discover disease mechanisms
[31]. Similar to drug treatments, diseases can also be treated as a type of perturbation to
the biological system of interest. Predicting disease targets may assist in identifying key




This dissertation describes three projects involving analysis and interpretation of big
biological data. These projects have demonstrated that computational approaches can help
to exploit those data and better understand drug or disease mechanisms at the systems
level for drug innovation and development. In the first project, we performed comparative
analysis of RNA-Seq data from mice treated with different adjuvants and identified the
mechanisms supporting adjuvant activity through collaboration with RIKEN institute in
Japan. This training project shows that analysis of RNA-Seq data can provide insights
for development of vaccine adjuvant. For the second project, we predicted immune cell
dynamics by linear regression-based or statistical algorithms and suggested a new approach
that can adjust gene expression to improve the discovery of key disease-associated genes.
In this project, gene expression of a biological system is connected with changes in cell
populations through computational tools. For the third project, it is shown that the network
topology predominantly defines the accuracy of a major drug target inference algorithm, and
we proposed a novel algorithm named TREAP, which integrates network betweenness and
differential gene expression to accurately predict drug targets in a time-efficient manner. It
is shown that computational approaches can connect molecular interaction data with gene
expression to explore drug mechanisms. Future work should focus on better balancing both
types of data and trying more sophisticated methods to improve the prediction accuracy of
TREAP.
At the time of writing, three peer-reviewed articles associated with this work have been
published. The work in predicting immune cell dynamics and key disease-associated genes
is published in IFAC [1] and Processes [2]. Part of the adjuvant project is recently accepted
by International Immunology [3], and one more article by our collaborators is expected. For
the work in drug target inference, the R package of TREAP is now available for public use
on GitHub, and the associated article is under review [4].
62
Appendix A
Supplementary Materials for Predicting Host Immune Cell Dynamics and Key
Disease-Associated Genes
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Figure 17: Scale-free topology fit using the WGCNA package for sample cohorts of (a) H1N1,
(b) pH1N1 and (c) H5N1.
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Figure 18: The estimated total number of cells in influenza virus-infected samples does not
change significantly in the 7-day time course. Since the fraction of a cell type is equal to the
number of this cell type divided by the total number of all cells in a sample, we have the
following equation to connect total cell numbers with cell fractions: ctxt = ft, where ct is a
vector of averaged cell fractions for n kinds of cells at time t predicted by CIBERSORT, ft
is a vector with the same length which represents averaged cell counts at time t measured
by FACS, and the total number of cells at time t is represented as xt. The values of xt at
all time points are estimated using linear regression (by the R function “lm”). We observe
that these xt values are relatively unvaried referring to the much smaller numbers of immune
cells.
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Figure 19: Cell counts of (a) total live cells, (b) T cell subsets, (c) neutrophils, DCs, NK
cells and NKT cells in mouse lungs after infection by either H1N1, pH1N1 or H5N1 virus.
Day 0 data are from uninfected, control animals. *Animals infected by H5N1 died before
Day 7.
66
Figure 20: Log fold change of estimated cell fractions by CIBERSORT in comparison with
log fold change of cell counts measured by FACS for different cell types. The black line is y
= x while the grey dashed line is regression.
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Figure 21: Log fold change of estimated cell fractions by MLLSR in comparison with log
fold change of cell counts measured by FACS for different cell types. The black line is y =
x while the grey dashed line is regression.
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Figure 22: Estimated cell quantities by (a) MLLSR, (b) CIBERSORT, (c) CTen, and (d)
DCQ in comparison with normalized cell counts measured by FACS. The black line is y = x
while the grey dashed line is regression.
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Figure 23: Estimated fractions of diverse cell types across time using MLLSR.
70
Figure 24: Estimated fractions of diverse cell types across time using CIBERSORT.
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Figure 25: Estimated relative cell quantities by DCQ in comparison with the change in
normalized cell counts for different cell types. The black line is y = x while the grey dashed
line is regression.
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Figure 26: Estimated relative quantities of diverse cell types across time using DCQ.
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Figure 27: Normalized eigengene profiles by CTen WGCNA in comparison with log fold
change of cell counts measured by FACS for different cell types. The black line is y = x
while the grey dashed line is regression.
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Figure 28: Normalized eigengene profiles of modules that are enriched in immune cells.
Negative submodules are denoted by an extra minus sign.
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Figure 29: R2 values obtained by comparing predicted cell quantities with measured cell
counts are plotted against the average cell counts per cell type per sample cohort for each
algorithm: (a) MLLSR, (b) CIBERSORT, (c) DCQ (p-value = 0.02), and (d) CTen. The
red lines are regression lines with equations notated.
76
Table 2: Antibodies used in flow cytometry for each cell type. The signs “+” and “-” indicate
positive and negative, respectively, and “H” and “L” represent “High” and “Low”.
Cell type CD45 c-kit FceRIa DX5 CD11b CCR3 Gr-1 NK1.1 CD3 B220 CD4 CD8 F4/80 CD11c
Basophils + - + +
Eosinophils + + + L
Neutrophils + + H
B cells + - - +
NK cells + + -
NK T cells + + +
CD4+ T cells + + + -
CD8+ T cells + + - +
Macrophages + + or - + + or -
Dendritic cells + + or - - +
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Figure 30: Comparing the accuracy of ProTINA and DeMAND. Target predictions for DP14
were performed by ProTINA and DeMAND using different combinations of PPIs and PGIs.
Median AUROC values of both algorithms for the same network setup were paired in this
figure.
Figure 31: The number of interactions under different thresholds for (a) PPIs and (b) PGIs.
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Figure 32: Performance of ProTINA on DP14 using PPIs and PGIs of different sizes.
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Figure 33: Performance of ProTINA on DP14 using PGIs from seven different cell/tissue
types.
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Figure 34: Predicting drug targets by degree or betweenness values of PGIs for ‘lymphocytes
of B lineage’.
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Figure 35: Median AUROCs of permutation tests on TREAP. 1000 permutation tests were
performed on TREAP by randomizing the adjusted p-values for (a) DP14, (b) HepG2 and
(c) MP. The blue vertical line in each panel refers to the median AUROC obtained by
nonrandomized adjusted p-values.
Table 3: Correlation coefficients between degree or betweenness values and ProTINA scores
for each drug
Chemical PPI Betweenness PPI Degree PPI+PGI Betweenness PPI+PGI Degree
Methotrexate 0.087742531 0.163785854 0.08539042 0.162703305
Blebbistatin 0.104272731 0.208298699 0.101154834 0.206385715
Camptothecin 0.106773529 0.224629718 0.102677995 0.22257972
Doxorubicin hydrochloride 0.112366047 0.209255068 0.114547587 0.208590487
Cycloheximide 0.106752819 0.214713019 0.103710782 0.212780846
Aclacinomycin A 0.024457165 0.097451912 0.023567461 0.096106315
Etoposide 0.08955877 0.178118355 0.085989173 0.176166631
Geldanamycin 0.06588576 0.169664995 0.068120054 0.168338047
Mitomycin C 0.094832663 0.219806504 0.092439142 0.217374173
Rapamycin 0.085112721 0.210553157 0.079170771 0.207861041
Trichostatin A 0.114241504 0.220097701 0.110610214 0.218378627
Vincristine 0.065358257 0.150465205 0.061458669 0.148480301
Monastrol 0.106149223 0.190908313 0.103970923 0.18895624
H-7, Dihydrochloride 0.099692622 0.228612182 0.099731216 0.227556513
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